Pluri Inc. (PLUR)
NasdaqCM: PLUR
· Real-Time Price · USD
1.68
-0.07 (-4.00%)
At close: Aug 12, 2026, 11:32 AM
Pluri Inc. (PLUR) Stock Price, Analysis & Data
-4.00% (1D)
| Bid | 1.66 |
| Market Cap | 18.13M |
| Revenue (ttm) | 1.08M |
| Net Income (ttm) | -25.54M |
| Beta | 0.68 |
| EPS (ttm) | -2.9 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.88 |
| P/B (ttm) | -0.94 |
| P/S (ttm) | 16.80 |
| Earnings Date | n/a |
| Ask | 1.8 |
| Volume | 755 |
| Avg. Volume (20D) | 26,672 |
| Open | 1.75 |
| Previous Close | 1.75 |
| Day's Range | 1.68 - 1.75 |
| 52-Week Range | 1.45 - 5.68 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLUR
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal ce...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2003
Employees 127
Stock Exchange NasdaqCM
Ticker Symbol PLUR
Website https://www.pluri-biotech.com
Financial Performance
In 2025, Pluri's revenue was 1.34M, an increase of 309.82% compared to the previous year's 326K. Earnings were -22.58M, an increase of 8.11%.
Financial StatementsEarnings Surprise
Pluri has released their quarterly earnings on Nov 12, 2025:
Page 1 of 2